Abdelazeem, N., El Refaiee, A., Othman, S. (2022). I-KappaB Expression in Patient with Psoriasis Vulgaris. test, 3(2), 7-22. doi: 10.21608/ejmr.2022.231672
Nahed Omar Abdelazeem; Abdelaziz Abdel Salam El Refaiee; Shimaa Taha Othman. "I-KappaB Expression in Patient with Psoriasis Vulgaris". test, 3, 2, 2022, 7-22. doi: 10.21608/ejmr.2022.231672
Abdelazeem, N., El Refaiee, A., Othman, S. (2022). 'I-KappaB Expression in Patient with Psoriasis Vulgaris', test, 3(2), pp. 7-22. doi: 10.21608/ejmr.2022.231672
Abdelazeem, N., El Refaiee, A., Othman, S. I-KappaB Expression in Patient with Psoriasis Vulgaris. test, 2022; 3(2): 7-22. doi: 10.21608/ejmr.2022.231672

I-KappaB Expression in Patient with Psoriasis Vulgaris

Egyptian Journal of Medical Research
Article 1, Volume 3, Issue 2, April 2022, Pages 7-22    PDF (859.89 K)
Document Type: Original Article
DOI: 10.21608/ejmr.2022.231672
Authors
Nahed Omar Abdelazeem1; Abdelaziz Abdel Salam El Refaiee2; Shimaa Taha Othman2
1Dermatology department, Faculty of Medicine, Cairo University, Egypt
2Dermatology department, Faculty of Medicine, Beni-Suef University, Egypt
Abstract
The goal of this study is to measure serum level of I Kappa B in patients with psoriasis in comparison with healthy controls. 50 psoriatic patients and 40 age & gender matched apparently healthy controls were included in the study, patients were classified according to Psoriasis Area & Surface Index (PASI) score and serum samples for all participants were taken to measure I Kappa B level for each. The level of serum I Kappa B was found to be significantly lower in the patients (3.96 ±1.96)  than in controls (11.02 ±2.22). This difference was of statistical significance (p-value =0.001).
Keywords
Psoriasis; I Kappa B and NF-KB
References
  1. Krueger JG and Lowes MA. (2015). (Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques). J Invest Dermatol. 130(11):2654-63.
  2. Milčić D,  Janković S,  Vesić S,  Milinković M,  Marinković J, Ćirković A and Janković J.(2017).( Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based cross-sectional study).
  3. Tupikowska-Marzec M,  Kolačkov K , Zdrojowy-Wełna A,  Słoka NK, Szepietowski JC and Maj J.(2019). ( The Influence of FTO Polymorphism rs9939609 on Obesity, Some Clinical Features, and Disturbance of Carbohydrate Metabolism in Patients with Psoriasis). Biomed Res Int.73 (45):43_45. 
  4. Boehncke WH and Schön MP. (2015). (Psoriasis). Lancet. 386 (9997): 983–94.
  5. Laura C, Laura S and Paul E. (2016). (psoriasis pathogenesis).Hand Book of Psoriasis and Psoriatic Arthritis; 1: 7-16.
  6. Huxford T, Hoffmann A and Ghosh G. (2011). (Understanding the logic of IκB:NF-κB regulation in structural terms). Curr Top Microbiol Immunol .349:1–24.
  7. Lin AM, Rubin CJ and Khandpur R. (2011). ( Mast cells and neutrophils release IL-17 through extracellular trap formation inpsoriasis). J Immunol . 187:490–500.
  8. Nikhil Moorchung , Janmeet S. Kulaar , Manas Chatterjee , BijuVasudevan ,   Tanu Tripathi .(2013). (Role of NF‐κB in the pathogenesis of psoriasis elucidated by its staining in skin biopsy specimens).International journal of dermatology.53(5):570_574.
  9. Doger FK, Dikicioglu E and Ergin F.(2007). ( Nature of cell kinetics in psoriatic epidermis). J Cutan Pathol .34: 257–263.
  10. Knapp RG, Miller MC. Clinical epidemiology and biostatistics. Published by Williams &​ Wilkins; Malvern, Pa. : Harwal Pub. Co., C.
  11. Marten Beck, Krestin M, Peter G and Jorge lamboy .(2016). (Binding of NF-KB appears to twist The Ankyrin Repeat Domain of IKB). Biophysical journal.10:887-895.
  12. Mathes E, Wang L, Komives E and Ghosh G. (2010). (Flexible regions within IκBα create the ubiquitin-independent degradation signal). J Biol Chem 285(43):32927–32936.
  13. Savinova OV, Hoffmann A and Ghosh G. (2009). (The Nfkb1 and Nfkb2 proteins p105 and p100 function as the core of high-molecular-weight heterogeneous complexes). Mol Cell. 34(5):591–602.
  14. Bergqvist S, Alverdi V, Mengel B, Hoffmann A, Ghosh G and Komives EA. (2009). (Kinetic enhancement of NF-κB:DNA dissociation by IκBα). Proc Natl Acad Sci USA. 106(46):19328–19333.
  15. Wilson NJ. (2007). (Development, cytokine profile and function of human interleukin 17-producing helper T cells). Nat Immunol. 8(9):950–957.
  16. Sano S. (2005). (Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model). Nat Med 11(1):43–49.
  17. Hayden MS and Ghosh S. (2012). (NF‐kappaB, the first quarter‐century: remarkable progress and outstanding questions). Genes Dev 26, 203–234.
  18. Lin AM, Rubin CJ and Khandpur R. (2011). ( Mast cells and neutrophils release IL-17 through extracellular trap formation inpsoriasis). J Immunol . 187:490–500.
  19. Goldminz AM, Au SC and Kim N. (2013). (NF-κB: an essential transcription factor in psoriasis). J Dermatol Sci. 69:89–94.
  20. Totzke G, et al. (2006). (A novel member of the IkappaB family, human IkappaB-zeta, inhibits transactivation of p65 and its DNA binding). J Biol Chem. 281:12645–12654.
  21. Trinh DV, Zhu N, Farhang G, Kim BJ and Huxford T. (2008). (The nuclear IκB protein IκBζ specifically binds NF-κB p50 homodimers and forms a ternary complex on κB DNA). J Mol Biol. 379(1):122–135.
  22. Muromoto R, Hirao T, Tawa K, Hirashima K, Kon S and Kitai Y.(2016). (IL-17A plays a central role in the expression of psoriasis signature genes through the induction of IκB-ζ in keratinocytes). Int Immunol. 28(9):443–52.
  23. Johansen C, Mose M, Ommen P, Bertelsen T, Vinter H, Hailfinger S, Lorscheid S, Schulze-Osthoff K and Iversen L. (2015). (IκBζ is a key driver in the development of psoriasis). Proc Natl Acad Sci U S A. 112(43):E5825-33.
  24. Claus Johansen, Maike Mose, Pernille Ommen, Trine Bertelsen, Hanne Vinter and Stephan Hailfinger. (2015). (IκBζ is a key driver in the development of psoriasis). PNAS.112(20):122-142.
Statistics
Article View: 265
PDF Download: 200